Type 2 diabetes, obesity
Conditions
Interventions
Isomaltodextrin (IMD) 50g
maltodextrin (MD) 50g
Sponsors
Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine
Kansai Electric Power Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers without diabetes 2. Gender: Male and female 3. BMI(kg/m2) at screening: 18 or more; and 30 or less 4. Age (years) at screening: 20 or more; and 75 or less
Exclusion criteria
Exclusion criteria: 1. Individuals receiving anti-diabetic drugs 2. Individuals with renal impairment 3. Individuals with hepatic impairment 4. Individuals with history of cerebrovascular disorders and/or ischemic heart diseases 5. Individuals with heart failure (NYHA I-IV) 6. Individuals with history of GI surgery 7. Individuals with excess alcohol consumption 8. Individuals with low Hb values: male, < 13.0g/dL and female 12.5 g/dL 9. Individuals who cannot follow orders from chief investigator or sub investigator 10. Individuals enrolled in other clinical trials 11. Pregnant individuals or those suspected of pregnancy 12. Individuals who are judged as inappropriate to be enrolled in this trials by chief investigator or sub investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma levels of GIP and GLP-1 before and after ingestion of IMD or MD; and their area under the curves | — |
Secondary
| Measure | Time frame |
|---|---|
| Levels of glucose, insulin, C-peptide, and glucagon before and after ingestion of IMD or MD; and their area under the curves | — |
Countries
Japan
Contacts
Public ContactDaisuke Yabe
Kansai Electric Power Hospital Center for Diabetes, Endocrinology and Metabolism
Outcome results
None listed